Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same?

Drug Safety

Volumn 25, Issue 9, 2002, Pages 649-663

  Evans, Marc ^a   Rees, Alan ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450 3A4; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; ITRACONAZOLE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DEATH; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0036051323     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225090-00004     Document Type: Review

References (89)

1. Changes in population cholesterol levels and coronary heart disease deaths in seven countries
2. Long-term epidemiologic prediction of coronary disease: The Framingham experience
3. Relationship between baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular and all cause mortality and longevity
4. Coronary risk factors, endothelial function and atherosclerosis: A review
5. The pathogenesis of atehrosclerosis: A perspective for the 1990s
6. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S)
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland coronary prevention study
8. Reduction of LDL cholesterol by 25-60% in patients with primary hypercholsterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor
9. Effects of pravastatin on in patients with serum cholesterol levels between 5.2 to 7.8 mmol/l plus two additional atherosclerotic risk factors. The pravastatin multinational study group for cardiac risk patients
10. Expanded clinical evaluation of lovastati (EXCEL) study results: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia
11. Cerivastatin a new potent synthetic HMG Co A reductase inhibitor: Effect of 0.2mg daily in subjects with hypercholesterolaemia
12. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials
13. Mevinolin: A highly potent competitive inhibitor of hydroxymetylglutaryl-co enzyme A reductase and a cholesterol lowering agent
14. Comparative tolerability of the HMG-CoA reductase inhibitors
15. HMG-CoA reductase inhibitors and myotoxicity
16. Statins and the risk of polyneuropathy: A case control study
17. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in human
18. Clinical pharamacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
19. Atorvastatin a review of its pharamacology and therapeutic potential in the management of hyperlipidaemia
20. Cerivastatin: A review of its pharamacological properties and therapeutic efficacy in the management of hypercholesterolaemia
21. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: Are the statins mechanistically similar?
22. Does differing metabolism by cytochrome P450 have clinical importance?
23. In-vitro metabolism of simvastatin in humans identification of metabolizing enzyme systems and effect of the drug on hepatic P450s
24. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers
25. Atorvastatin calcium: An addition to HMG-CoA reductase inhibitors
26. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interaction
27. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the managemerit of coronary heart disease
28. Influence of erythromycin pre- and co-treatment on single dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
29. Metabolism of the new immunosuppresor cyclosporin G by human liver cytochrome P450
30. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
31. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
32. Statin-fibrate combination therapy
33. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
34. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
35. Role of peroxisome proliferator activated receptor in mediating effects of fibrates and fatty acids on gene expression
36. Combined treatment with specific ligands for PPARgamma: RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells
37. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter
38. PPAR gamma and the treatment of insulin resistance
39. Rosiglitazone in combination with a statin: Effect on lipid profile in patients with type 2 diabetes
40. Drug-induced myopathies in man
41. Binding of drugs to human muscle
42. Metabolic causes of recurrent rhabdomyolysis
43. Rhabdomyolysis
44. Prava-induced rhabdomyolysis in a patient with mixed connective tissue disease
45. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
46. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Cholesterol And Recurrent Events
47. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
48. MRC/BHF heart protection study of cholesterol lowering and antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease
49. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin
50. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) study group
51. Safety and tolerability of pravastatin in long-term clinical trials: Pravastatin pooling project
52. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. Lipoprotein and Coronary Atherosclerosis Study [LCAS]
53. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial
54. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
55. Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia
56. Combination therapy with fluvastatin and niacin in hypercholesterolaemia: A preliminary report on safety
57. Cerivastatin and primary hyperlipidaemia: A multicenter analysis of safety and efficacy
58. Clinical pharmacokinetics of cerivastatin
59. Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study
60. Learning from the cerivastatin experience
61. Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy
62. Rhabdomyolysis from high-dose cerivastatin therapy
63. Lova-induced acute rhabdomyolysis
64. Acute muscular syndrome associated with administration of clofibrate
65. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy
66. The role of cholesterol lowering agents in drug induced rhabdomyolysis and polymyositis
67. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors
68. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
69. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolaemic patients
70. Reduction of plasma cholesterol by lovastatin in patients with severe hypercholesterolaemia
71. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin
72. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems
73. A disorder of muscle lipid metabolism and myoglobinuria: Absence of carnitine palmityl transferase
74. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovostatin monotherapy
75. Effect of 3-hydroxy-3-methyl coenzyme A reductase inhibiton on human gut mucosa
76. Mitochondria in neuromuscular disorders
77. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
78. Polymyositis associated with simvastatin
79. Pravastatin associated inflammatory myopathy
80. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
81. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
82. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
83. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes
84. Rhabdomyolysis after atorvastatin with gemfibrozil
85. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
86. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
87. Plasma concentrations of lovastatin are increased by gemfibrozil but not by bezafibrate
88. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9
89. Statin-fibrate combination therapy